Valeant Pharmaceuticals International, Inc. reports that its wholly owned subsidiary, Valeant Canada, is expanding its Canadian manufacturing and export capacity with investments totaling $27.5 million in its Steinbach, Manitoba and Laval, Quebec manufacturing facilities.

Valeant will invest $15 million in its Steinbach, Manitoba facility by the end of 2016, including $7 million in upgrades to product manufacturing technology and $8 million for the transfer of North American production of Xifaxan (rifaximin) and Apriso (mesalamine). Xifaxan is prescribed to relieve symptoms of hepatic encephalopathy and irritable bowel syndrome, and Apriso is used to treat ulcerative colitis. These investments will support the facility’s growth and expand its role as an exporter of healthcare products through international distribution channels. Since 2012, Valeant has transferred 27 technologies to Steinbach for manufacturing.

Valeant also announced $12.5 million of investments in its Laval, Quebec facility, which includes $10 million to upgrade product manufacturing technology as well as $2.5 million associated with the transfer of production of Arestin (minocycline hydrochloride) to Laval. The transfer of Arestin, an antibiotic treatment for periodontal disease, will create 15 new engineering and production jobs and builds upon the transfer of Jublia (efinaconazole) production to Quebec earlier this year. Since 2012, Valeant has transferred numerous technologies to Laval, resulting in the production of 67 new products.

Source: Valeant Pharmaceuticals